Outcomes of Gemcitabine Treatment for Invasive Ductal Pancreatic Cancer

Suizo
doi 10.2958/suizo.22.30
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Japan Pancreas Society

Related search

Galunisertib Plus Gemcitabine vs. Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

The Anti-Fibrotic Effect of GV1001 Combined With Gemcitabine on Treatment of Pancreatic Ductal Adenocarcinoma

Oncotarget
Oncology
2016English

Performance Status Dynamics During Treatment With Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone for Metastatic Pancreatic Cancer

Cancer Management and Research
Oncology
2018English

Front Cover: A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma (ChemMedChem 15/2019)

ChemMedChem
Organic ChemistryMolecular MedicinePharmacologyBiochemistryToxicologyDrug DiscoveryPharmaceutics
2019English

Pancreatic Metastasis From Invasive Ductal Carcinoma of the Breast

The Korean Journal of Medicine
2017English

FKBP5 as a Selection Biomarker for Gemcitabine and Akt Inhibitors in Treatment of Pancreatic Cancer

PLoS ONE
Multidisciplinary
2012English

Adjuvant Chemotherapy With Gemcitabine and Long-Term Outcomes Among Patients With Resected Pancreatic Cancer

JAMA - Journal of the American Medical Association
Medicine
2013English

Establishment and Characterization of the Gemcitabine‑resistant Human Pancreatic Cancer Cell Line SW1990/gemcitabine

Oncology Letters
Cancer ResearchOncology
2019English

Comparison of Clinical Outcomes Between Luminal Invasive Ductal Carcinoma and Luminal Invasive Lobular Carcinoma

BMC Cancer
Cancer ResearchOncologyGenetics
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy